Plantibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Transgenic Crop (Tobacco, Legumes, Cereals, Seeds & Tubers, Fruits & Vegetables, Others), By Technique (Conventional Method, Tissue Culture, Breeding & Sexual Crossing, Transgenic Seeds, Others), By Application (Autoimmune Diseases, Cancer, Infectious Diseases, Immunization, Dentistry, Others), By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutes, Others), By Region and Competition, 2020-2030F

November 2025 | 185 pages | ID: PC0198AAF8E7EN
TechSci Research

Abstracts

The Global Plantibodies Market , valued at USD 60.91 Million in 2024, is projected to experience a CAGR of 8.18% to reach USD 97.63 Million by 2030. Plantibodies are recombinant antibodies produced in genetically modified plants, designed for diverse therapeutic and diagnostic applications. The market's growth is predominantly supported by the intrinsic advantages of plant-based expression systems, notably lower production costs, superior scalability compared to conventional mammalian cell cultures, and a mitigated risk of contamination from human or animal pathogens. These systems also offer accelerated production timelines due to the rapid growth characteristics of host plants.

Key Market Drivers

The Global Plantibodies Market is primarily driven by cost-effective production and scalability, along with a significantly reduced risk of pathogen contamination. Plant-based expression systems inherently bypass the high capital investments and operational costs associated with traditional mammalian cell cultures, which demand complex sterile bioreactor environments. This allows for scalable cultivation in diverse settings, enabling high-volume biopharmaceutical production at lower per-unit expenses. According to the National Science Foundation's Partnerships for Innovation Research Partnerships (PFI-RP) project, in its 2024 abstract, plant-based biomanufacturing platforms target production exceeding 500 mg per kilogram of plant fresh weight for functional human blood proteins, demonstrating substantial scalability.

Key Market Challenges

The intricate and developing regulatory landscape for plant-derived pharmaceuticals poses a substantial impediment to the growth of the Global Plantibodies Market. The evolving nature of guidelines for genetically modified organisms used in therapeutic production creates uncertainty for developers and investors alike. This complexity often translates into extended timelines for product development and approval, delaying market entry for innovative plantibody candidates.

The compliance burden imposed by diverse and sometimes overlapping regulations significantly increases operational costs for companies engaged in plantibody manufacturing. According to the National Association of Manufacturers, the average manufacturer in the United States incurred over $29,000 per employee per year in federal regulatory compliance costs in 2022, measured in 2023 dollars. This substantial financial overhead, applicable across the manufacturing sector, directly impacts the economic viability of novel plant-based biopharmaceutical ventures.

Key Market Trends

The integration of artificial intelligence into plantibody discovery and optimization is accelerating development timelines and enhancing therapeutic precision. AI algorithms efficiently analyze extensive protein data, predicting optimal modifications for improved binding affinity and efficacy, thereby streamlining initial drug development phases. According to PhRMA, the biopharmaceutical industry invested nearly $101 billion in research and development in 2022, highlighting the sector’s robust commitment to innovation enabling advanced computational methods. For example, Stanford scientists developed a machine learning method achieving a 25-fold improvement in a SARS-CoV-2 antibody by predicting molecular changes, as reported in Science in July 2024. This showcases AI's direct influence on identifying highly effective plantibody variants.

Key Market Players

• PlantForm Corporation
• Planet Biotechnology Inc.
• iBio, Inc.
• Mapp Biopharmaceutical, Inc. (Allergan, Inc.)
• Medicago Inc.
• NOMAD Bioscience GmbH
• Ventria Bioscience Inc.
• Agrisera AB
• Creative Biolabs, Inc.
• Protalix BioTherapeutics Inc.

Report Scope:

In this report, the Global Plantibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Plantibodies Market , By Transgenic Crop:
• Tobacco
• Legumes
• Cereals
• Seeds & Tubers
• Fruits & Vegetables
• Others
• Plantibodies Market , By Technique:
• Conventional Method
• Tissue Culture
• Breeding & Sexual Crossing
• Transgenic Seeds
• Others
• Plantibodies Market , By Application:
• Autoimmune Diseases
• Cancer
• Infectious Diseases
• Immunization
• Dentistry
• Others
• Plantibodies Market , By End User:
• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutes
• Others
• Plantibodies Market , By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Plantibodies Market .

Available Customizations:

Global Plantibodies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL PLANTIBODIES MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Transgenic Crop (Tobacco, Legumes, Cereals, Seeds & Tubers, Fruits & Vegetables, Others)
  5.2.2. By Technique (Conventional Method, Tissue Culture, Breeding & Sexual Crossing, Transgenic Seeds, Others)
  5.2.3. By Application (Autoimmune Diseases, Cancer, Infectious Diseases, Immunization, Dentistry, Others)
  5.2.4. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutes, Others)
  5.2.5. By Region
  5.2.6. By Company (2024)
5.3. Market Map

6. NORTH AMERICA PLANTIBODIES MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Transgenic Crop
  6.2.2. By Technique
  6.2.3. By Application
  6.2.4. By End User
  6.2.5. By Country
6.3. North America: Country Analysis
  6.3.1. United States Plantibodies Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Transgenic Crop
      6.3.1.2.2. By Technique
      6.3.1.2.3. By Application
      6.3.1.2.4. By End User
  6.3.2. Canada Plantibodies Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Transgenic Crop
      6.3.2.2.2. By Technique
      6.3.2.2.3. By Application
      6.3.2.2.4. By End User
  6.3.3. Mexico Plantibodies Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Transgenic Crop
      6.3.3.2.2. By Technique
      6.3.3.2.3. By Application
      6.3.3.2.4. By End User

7. EUROPE PLANTIBODIES MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Transgenic Crop
  7.2.2. By Technique
  7.2.3. By Application
  7.2.4. By End User
  7.2.5. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Plantibodies Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Transgenic Crop
      7.3.1.2.2. By Technique
      7.3.1.2.3. By Application
      7.3.1.2.4. By End User
  7.3.2. France Plantibodies Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Transgenic Crop
      7.3.2.2.2. By Technique
      7.3.2.2.3. By Application
      7.3.2.2.4. By End User
  7.3.3. United Kingdom Plantibodies Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Transgenic Crop
      7.3.3.2.2. By Technique
      7.3.3.2.3. By Application
      7.3.3.2.4. By End User
  7.3.4. Italy Plantibodies Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Transgenic Crop
      7.3.4.2.2. By Technique
      7.3.4.2.3. By Application
      7.3.4.2.4. By End User
  7.3.5. Spain Plantibodies Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Transgenic Crop
      7.3.5.2.2. By Technique
      7.3.5.2.3. By Application
      7.3.5.2.4. By End User

8. ASIA PACIFIC PLANTIBODIES MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Transgenic Crop
  8.2.2. By Technique
  8.2.3. By Application
  8.2.4. By End User
  8.2.5. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Plantibodies Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Transgenic Crop
      8.3.1.2.2. By Technique
      8.3.1.2.3. By Application
      8.3.1.2.4. By End User
  8.3.2. India Plantibodies Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Transgenic Crop
      8.3.2.2.2. By Technique
      8.3.2.2.3. By Application
      8.3.2.2.4. By End User
  8.3.3. Japan Plantibodies Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Transgenic Crop
      8.3.3.2.2. By Technique
      8.3.3.2.3. By Application
      8.3.3.2.4. By End User
  8.3.4. South Korea Plantibodies Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Transgenic Crop
      8.3.4.2.2. By Technique
      8.3.4.2.3. By Application
      8.3.4.2.4. By End User
  8.3.5. Australia Plantibodies Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Transgenic Crop
      8.3.5.2.2. By Technique
      8.3.5.2.3. By Application
      8.3.5.2.4. By End User

9. MIDDLE EAST & AFRICA PLANTIBODIES MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Transgenic Crop
  9.2.2. By Technique
  9.2.3. By Application
  9.2.4. By End User
  9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Plantibodies Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Transgenic Crop
      9.3.1.2.2. By Technique
      9.3.1.2.3. By Application
      9.3.1.2.4. By End User
  9.3.2. UAE Plantibodies Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Transgenic Crop
      9.3.2.2.2. By Technique
      9.3.2.2.3. By Application
      9.3.2.2.4. By End User
  9.3.3. South Africa Plantibodies Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Transgenic Crop
      9.3.3.2.2. By Technique
      9.3.3.2.3. By Application
      9.3.3.2.4. By End User

10. SOUTH AMERICA PLANTIBODIES MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Transgenic Crop
  10.2.2. By Technique
  10.2.3. By Application
  10.2.4. By End User
  10.2.5. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Plantibodies Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Transgenic Crop
      10.3.1.2.2. By Technique
      10.3.1.2.3. By Application
      10.3.1.2.4. By End User
  10.3.2. Colombia Plantibodies Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Transgenic Crop
      10.3.2.2.2. By Technique
      10.3.2.2.3. By Application
      10.3.2.2.4. By End User
  10.3.3. Argentina Plantibodies Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Transgenic Crop
      10.3.3.2.2. By Technique
      10.3.3.2.3. By Application
      10.3.3.2.4. By End User

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL PLANTIBODIES MARKET : SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. PlantForm Corporation
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. Planet Biotechnology Inc.
15.3. iBio, Inc.
15.4. Mapp Biopharmaceutical, Inc. (Allergan, Inc.)
15.5. Medicago Inc.
15.6. NOMAD Bioscience GmbH
15.7. Ventria Bioscience Inc.
15.8. Agrisera AB
15.9. Creative Biolabs, Inc.
15.10. Protalix BioTherapeutics Inc.

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER